Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Atezolizumab in High-Risk Cutaneous Melanoma
NCT04020809Phase 1Active, not recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Sep 2020
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in cutaneous melanoma (CM), sponsored by Houston Methodist Research Institute. Primary endpoints: Number of participants completing neoadjuvant atezolizumab at 63 months and Number of participants with treatment-related adverse events at 63 months. Started Sep 2020; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT04020809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04020809.